New RNA-Seq Service Uses Illumina Sequencing Techniques

Press Release Summary:

• Designed for input amounts down to 2 pg, applicable for good quality RNA from challenging samples
• Offers a powerful tool for analyzing the gene expression in cancer research and studies
• Allows to detect splice junctions and significant changes in gene expression for low abundant transcripts

Original Press Release:

CD Genomics: Ultralow Input RNA-Seq Service Now Available by RNA Solutions Platform

RNA Solutions is a platform that offers services for the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. CD Genomics is proud to launch the ultralow input R.0NA-seq service using leading-edge Illumina sequencing techniques.

The highly sensitive ultralow input RNA-Seq service enables researchers to explore the gene expression profile with the ultra-low amount of input RNA. This technique offers a powerful tool for analyzing the gene expression in cancer research and studies with extremely rare samples.

Understanding the cellular heterogeneity of tissues such as tumors is crucial for both translational and clinical research. As a result, highly focused techniques such as single-cell RNA sequencing (scRNA-seq) and ultra-low-input mRNA-seq are expanding rapidly to overcome the challenges that single cells and restricted cell populations. RNA-seq can be used to understand the complex biology of gene regulation and assist in understanding gene expression from ultra-low, high-quality total RNA or intact cells (both bulk or single cell).

Ultralow input RNA sequencing (RNA-seq) is a powerful tool for gene expression profiling with limited number of cells, especially when cell-to-cell variation are not the aim. It allows you to detect splice junctions and significant changes in gene expression for low abundant transcripts, as well as discovery of biomarkers and transcription-factors.

“CD Genomics offers a simple, low-cost, and low-bias ultralow input RNA-seq with Illumina sequencing. When the experimental and computational optimizations are combined, the solution can be comparable to bulk RNA-seq, minimizing bias with far fewer mappable reads. Our ultralow input RNA sequencing service is specifically designed for input amounts down to 2 pg, applicable for good quality RNA from challenging samples. Our expert team ensures you uniform transcript coverage even with ultralow input amount. Built on a foundation of unmatched expertise in transcriptomics, CD Genomics is highly experienced in ultralow input RNA-seq and bioinformatic analysis,” said the Chief Scientist of CD Genomics.

CD Genomics will continue to develop innovative chemical methods with increased sensitivity to detect more complex and low-abundance transcripts, while reducing the cost per study and making it more accessible to all laboratories. NGS product development continues to focus on providing customers with better solutions that enable them to conduct important research in a variety of biological fields where single-cell data is critical, especially in those elusive fields such as cancer research, developmental biology, neurobiology and immunology.

About CD Genomics

CD Genomics enjoys a high reputation for sequencing, microarray analysis, library construction and genotyping, providing reliable services to pharmaceutical and biotechnology companies as well as academia and government agencies.